Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | PHASE1 | NOT YET_RECRUITING | 104 | — | — | Oct 1, 2025 | Oct 1, 2032 | Sep 9, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| RYZ401 | DRUG | Ac-225 |